Detalhe da pesquisa
1.
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Oncologist
; 28(9): e703-e711, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36940301
2.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol
; 23(12): 1571-1582, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370716
3.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1458-1467, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543613
4.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
5.
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Int J Cancer
; 147(1): 160-169, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724170
6.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
BMC Med
; 17(1): 207, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31747948
7.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326029
8.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 474-485, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29482983
9.
Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
Breast Cancer Res
; 19(1): 106, 2017 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893303
10.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â×â2 factorial, randomised phase 3 trial.
Lancet
; 385(9980): 1863-72, 2015 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25740286
11.
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Future Oncol
; 12(22): 2589-2602, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27443691
12.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Oncologist
; 20(9): 1001-10, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26245675
13.
Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Ann Surg Oncol
; 22(9): 2881-7, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25572687
14.
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Cancer Immunol Res
; 12(1): 120-134, 2024 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37856875
15.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
J Natl Cancer Inst
; 116(1): 69-80, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676829
16.
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
EClinicalMedicine
; 70: 102501, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685923
17.
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
NPJ Breast Cancer
; 9(1): 6, 2023 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739285
18.
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
J Clin Oncol
; 41(32): 4976-4981, 2023 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748109
19.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Clin Cancer Res
; 29(17): 3429-3437, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37417941
20.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
J Immunother Cancer
; 11(11)2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016718